SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after announcing robust vehicle deliveries for December and the fourth quarter, reaching new highs and demonstrating significant annual growth. The community is actively discussing the potential for imminent profitability, buoyed by strong sales performance and recently extended government subsidies favoring NEVs, positioning NIO ahead of its Chinese counterparts. Despite positive operational momentum, many investors are capitalizing on price dips, anticipating a strong market response as the company's fundamentals continue to improve.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is trending as investors weigh its full-year vehicle delivery growth, which more than doubled despite missing some recent quarterly guidance, against intense competition in the Chinese EV sector. The community is actively discussing newly extended government subsidies for electric vehicles into 2026 and the company's aggressive global expansion, including new market entries and local production initiatives. Despite recent volatility and comparisons to rivals, many believe the stock is undervalued, highlighting its advancements in AI, robotics, and autonomous driving capabilities as key future drivers.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

The Dogecoin community is abuzz with divided sentiment, as year-end activities like tax loss selling appear to be influencing recent price action. While some express frustration over current levels, a resilient cohort of investors anticipates a strong rebound and potential rallies in the coming year, fueled by hopes for future market cycles. The ongoing debate centers on whether this period marks a prime accumulation opportunity or a signal for further caution.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending as it expands its anticoagulation pipeline, notably with the acquisition of VLX-1005 and strategic advancements for its lead candidate, Tecarfarin, including manufacturing progress and a collaboration with Abbott for its pivotal Phase 3 trial. Community sentiment is divided, with proponents highlighting the low float and significant market potential, while critics raise concerns about dilution and financial sustainability.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is actively trending after a competitor's Cushing's syndrome treatment received a regulatory decline, clearing a significant market hurdle for Xeris's approved drug, Recorlev. The community is buzzing about this as a massive tailwind, expecting substantial market share gains that bolster XERS's already strong financial performance and promising pipeline. Analysts are reflecting this positive outlook, highlighting the company's compelling growth trajectory.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is trending due to its strategic sale of Bressner Technology, which has boosted its cash reserves and sharpened its focus on core AI and edge computing. The community is actively discussing the company's recent stronger-than-expected earnings and raised guidance, alongside high anticipation for a significant military contract for 360 situational awareness systems. Many investors view OSS as an undervalued pure-play in the growing Edge AI and defense sectors, highlighting its tight float and institutional interest.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending as the community anticipates potential catalysts from CES 2026 and a market rebound in January, following a period of significant price decline attributed by some to year-end tax loss selling. Bullish investors highlight the company's voice AI technology, substantial contractual backlog, and long-term growth prospects, while skeptics point to insider selling and a lack of immediate news as reasons for caution within the rapidly evolving AI landscape.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bear 3X Shares

LABD is trending amid intense frustration as the biotech sector's (XBI) extended bullish rally continues to defy expectations, leading to significant pressure on this 3x leveraged bear ETF. The community is sharply divided, with many anticipating an imminent, overdue reversal due to XBI's stretched technicals and high RSI, while others caution against fighting the sector's persistent upward momentum.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending due to a significant stock decline following the FDA's Complete Response Letter for its Relacorilant drug, which cited a need for additional efficacy evidence for Cushing's-related hypertension. The community is actively debating if the sharp sell-off is an overreaction, pointing to the company's established revenue-generating drug and diverse pipeline as reasons for a potential undervaluation. Many are discussing whether this regulatory setback, interpreted by some as extreme, presents a unique buying opportunity amidst year-end market dynamics.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending sharply higher following the FDA's acceptance of its sNDA for AXS-05 in Alzheimer's disease agitation with Priority Review, setting a PDUFA target in April 2026. This significant regulatory clarity, coupled with positive updates for AXS-12 in narcolepsy and continued strong Auvelity script growth, is fueling widespread optimism among investors. The community is celebrating substantial long-term gains and actively discussing AXSM's potential to become a major CNS powerhouse, anticipating further analyst upgrades and robust performance as the company advances its diverse pipeline and commercial footprint.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


kimthinhphat1

ĐÁ HOA CƯƠNG KIM THỊNH PHÁT